Biotechnology -- Deutsche Banc Alex. Brown's Dennis Harp Expands Research Coverage of the Sector

Apr 12, 2001, 01:00 ET from Deutsche Banc Alex. Brown

    NEW YORK, April 12 /PRNewswire/ -- Deutsche Banc Alex. Brown analyst
 Dennis Harp today expanded his coverage of the biotechnology and genomics
 sector with the initiation of CV Therapeutics, Inc. (Nasdaq: CVTX)($36.04),
 MedImmune, Inc. (Nasdaq: MEDI)($35.00), and Millennium Pharmaceuticals, Inc.
 (Nasdaq: MLNM)($31.01).  CV Therapeutics was started with a STRONG BUY
 investment rating, while MedImmune and Millennium Pharmaceuticals were started
 with an investment rating of BUY.
     According to Harp's investment thesis, the sequencing of the human genome
 has been an historical milestone and resulted in an unprecedented
 understanding of genes, their functions and how they differ from each
 individual.  Harp stated, "Greater understanding of human genes, their
 function and how they differ from individual to individual already has
 accelerated the rate of drug discovery and will transform the practice of
 medicine-making possible more tailored drug therapies for the first time.
 Leading biotechnology and genomics companies pioneering our understanding of
 the human genome will experience explosive revenue and earnings growth and
 should be part of any high growth or health care stock portfolio."
     In Harp's opinion, CV Therapeutics, MedImmune and Millennium possess one
 or more of the following attributes, which he believes are characteristic of
 leading biotechnology companies, and are compatible with his investment theme
 of selectively investing in such leading companies.
 
     -- Leading market share positions for marketed products.
 
     -- Development of breakthrough products to treat major diseases with
        opportunities for such drugs to become the standard of care and serve a
        large patient populations.
 
     -- Establishment of dominant intellectual property positions.
 
     Deutsche Banc Alex. Brown represents the Investment Banking activities of
 Deutsche Banc Alex. Brown Inc. (US) and Deutsche Bank Securities Ltd.
 (Canada). Deutsche Banc Alex. Brown and Deutsche Bank Securities Ltd. are
 subsidiaries of Deutsche Bank AG.  With assets of about Euro 940 billion and
 more than 98,000 employees, Deutsche Bank offers its clients unparalleled
 financial services throughout the world in over 60 countries. It ranks among
 the leaders in asset management, capital markets, corporate finance, custody,
 cash management and private banking. Deutsche Bank is organised in two
 customer-oriented Groups: "Corporate and Investment Bank" (CIB) and "Private
 Clients and Asset Management" (PCAM). The keys to the Bank's success remain
 constant: customer focus, the spirit of innovation, a broad range of product
 skills combined with technological power and financial strength delivered by
 highly skilled professionals.
     Millennium Pharmaceuticals, Inc., CV Therapeutics, Inc., and MedImmune,
 Inc. stocks are optionable.
     CV Therapeutics, Inc. has a convertible issue outstanding.
 
     Information herein is believed to be reliable and has been obtained from
 sources believed to be reliable, but its accuracy and completeness cannot be
 guaranteed.  Opinions, estimates, and projections constitute our judgment and
 are subject to change without notice.  This publication is provided to you for
 information purposes only and is not intended as an offer or solicitation for
 the sale of any financial instrument.  Deutsche Banc Alex. Brown Inc. and its
 affiliates worldwide, may hold a position or act as market maker in the
 financial instruments of any issuer discussed herein or act as advisor or
 lender to such issuer.  Transactions should be executed through a Deutsche
 Bank entity in the client's home jurisdiction unless otherwise permitted by
 law.  Deutsche Banc Alex. Brown Inc. is a member of NYSE and NASD.
 
 

SOURCE Deutsche Banc Alex. Brown
    NEW YORK, April 12 /PRNewswire/ -- Deutsche Banc Alex. Brown analyst
 Dennis Harp today expanded his coverage of the biotechnology and genomics
 sector with the initiation of CV Therapeutics, Inc. (Nasdaq: CVTX)($36.04),
 MedImmune, Inc. (Nasdaq: MEDI)($35.00), and Millennium Pharmaceuticals, Inc.
 (Nasdaq: MLNM)($31.01).  CV Therapeutics was started with a STRONG BUY
 investment rating, while MedImmune and Millennium Pharmaceuticals were started
 with an investment rating of BUY.
     According to Harp's investment thesis, the sequencing of the human genome
 has been an historical milestone and resulted in an unprecedented
 understanding of genes, their functions and how they differ from each
 individual.  Harp stated, "Greater understanding of human genes, their
 function and how they differ from individual to individual already has
 accelerated the rate of drug discovery and will transform the practice of
 medicine-making possible more tailored drug therapies for the first time.
 Leading biotechnology and genomics companies pioneering our understanding of
 the human genome will experience explosive revenue and earnings growth and
 should be part of any high growth or health care stock portfolio."
     In Harp's opinion, CV Therapeutics, MedImmune and Millennium possess one
 or more of the following attributes, which he believes are characteristic of
 leading biotechnology companies, and are compatible with his investment theme
 of selectively investing in such leading companies.
 
     -- Leading market share positions for marketed products.
 
     -- Development of breakthrough products to treat major diseases with
        opportunities for such drugs to become the standard of care and serve a
        large patient populations.
 
     -- Establishment of dominant intellectual property positions.
 
     Deutsche Banc Alex. Brown represents the Investment Banking activities of
 Deutsche Banc Alex. Brown Inc. (US) and Deutsche Bank Securities Ltd.
 (Canada). Deutsche Banc Alex. Brown and Deutsche Bank Securities Ltd. are
 subsidiaries of Deutsche Bank AG.  With assets of about Euro 940 billion and
 more than 98,000 employees, Deutsche Bank offers its clients unparalleled
 financial services throughout the world in over 60 countries. It ranks among
 the leaders in asset management, capital markets, corporate finance, custody,
 cash management and private banking. Deutsche Bank is organised in two
 customer-oriented Groups: "Corporate and Investment Bank" (CIB) and "Private
 Clients and Asset Management" (PCAM). The keys to the Bank's success remain
 constant: customer focus, the spirit of innovation, a broad range of product
 skills combined with technological power and financial strength delivered by
 highly skilled professionals.
     Millennium Pharmaceuticals, Inc., CV Therapeutics, Inc., and MedImmune,
 Inc. stocks are optionable.
     CV Therapeutics, Inc. has a convertible issue outstanding.
 
     Information herein is believed to be reliable and has been obtained from
 sources believed to be reliable, but its accuracy and completeness cannot be
 guaranteed.  Opinions, estimates, and projections constitute our judgment and
 are subject to change without notice.  This publication is provided to you for
 information purposes only and is not intended as an offer or solicitation for
 the sale of any financial instrument.  Deutsche Banc Alex. Brown Inc. and its
 affiliates worldwide, may hold a position or act as market maker in the
 financial instruments of any issuer discussed herein or act as advisor or
 lender to such issuer.  Transactions should be executed through a Deutsche
 Bank entity in the client's home jurisdiction unless otherwise permitted by
 law.  Deutsche Banc Alex. Brown Inc. is a member of NYSE and NASD.
 
 SOURCE  Deutsche Banc Alex. Brown